Summary of Arvinas Conference Call Company Overview - **Company**: Arvinas - **Industry**: Biotechnology - **Focus**: Development of targeted protein degraders (PROTACs) for various diseases, including neurodegenerative disorders and cancers Key Points and Arguments Current Pipeline and Programs - Arvinas has four programs in Phase 1 as of 2026, including: - LRRK2 degrader for neurodegenerative disorders - KRAS G12D degrader for solid tumors - BCL6 degrader for hematology - A new program targeting AR for Kennedy's disease, recently initiated [2][3][4] Vepdegestrant Program - The previously leading program, vepdegestrant (an ER degrader), has positive pivotal data and an NDA filed with the FDA, with a PDUFA date in early June [3][8] - The company is actively seeking partnerships for this program, with discussions progressing well [8] LRRK2 Program Insights - The LRRK2 program (ARV-102) is expected to provide data soon, with a focus on its role in Parkinson's disease and progressive supranuclear palsy [10][12] - Preclinical data shows increased lysosome number and capacity, indicating potential benefits for patients [11] Differentiation Strategy - Emphasis on creating differentiated clinical candidates and ensuring the right use of technology [6] - The company aims to leverage its PROTAC platform to develop unique therapies that outperform existing treatments [5] KRAS Program - The KRAS G12D degrader (ARV-806) is noted for its ability to remove the oncoprotein from tumors, showing 25-fold greater potency than existing clinical mechanisms [47] - The program is designed to avoid the rapid resynthesis of the oncoprotein seen with inhibitors, aiming for durable degradation [50][60] - Initial data readouts will focus on safety and potential efficacy, with a need to differentiate from competitors [59][60] BCL6 Program - The BCL6 degrader (ARV-393) is in Phase 1, with data expected in the second half of the year [75] - The program will explore both monotherapy and combination studies, particularly with glofitamab [80] Market Opportunity - Progressive supranuclear palsy is highlighted as a rare but significant market, with approximately 25,000 diagnosed patients in the U.S. [42] - The company is positioned to address unmet needs in both neurodegenerative diseases and oncology, with a focus on innovative treatment approaches [39][40] Future Development and Partnerships - The company is open to partnerships for advancing its programs, especially in competitive areas like KRAS [70] - Plans to start a Phase 1b trial in patients with progressive supranuclear palsy within the year [32] Additional Important Content - The company is committed to ensuring that its therapies are available to patients as soon as possible upon FDA approval [8] - The focus on differentiation and the potential for combination therapies is critical for success in a crowded market [60][70] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Arvinas' commitment to innovation in biotechnology and its proactive approach to navigating competitive landscapes.

Summary of Arvinas Conference Call Company Overview - **Company**: Arvinas (NasdaqGS:ARVN) - **Focus**: Development of PROTAC degraders, with four programs currently in phase one across various disease areas [5][6] Key Programs and Developments - **Pipeline**: - **Vepdegestrant**: Positive pivotal phase trial readout for ER degrader [6] - **Bavdegalutamide**: Outlicensed to Novartis, providing a strong foundation for future growth [6] - **ARV-102**: LRRK2 degrader targeting neurodegeneration, showing promise in reducing LRRK2 levels in cerebrospinal fluid [39][40] - **ARV-806**: KRAS G12D degrader for solid tumors, with rapid enrollment in clinical trials [128] - **ARV-393**: BCL6 degrader in phase 1 studies for B-cell and T-cell lymphomas, showing early responses [142][143] - **ARV-027**: Polyglutamine repeat AR degrader for Kennedy's disease, recently started in clinical trials [145] - **ARV-6723**: HPK1 degrader planned for future clinical use [146] Competitive Advantages - **PROTAC Technology**: - Allows for iterative degradation, overcoming resistance mechanisms that traditional inhibitors face [27][28] - Offers oral bioavailability and the ability to cross the blood-brain barrier, which is advantageous for treating neurodegenerative diseases [28] - **Differentiation**: Each program is focused on demonstrating unique benefits over existing therapies, such as improved efficacy and reduced resistance [20][21] Market Position and Strategy - **Commercialization**: Arvinas is seeking a new partner for the commercialization of vepdegestrant while focusing resources on earlier pipeline assets [18][19] - **Combination Therapies**: Emphasis on developing combination strategies, particularly for oncology applications, to enhance treatment efficacy [139] Clinical Insights - **LRRK2 and Neurodegeneration**: - Targeting LRRK2 is crucial for diseases like Parkinson's and progressive supranuclear palsy, with a goal to reduce LRRK2 levels by 50% to halt disease progression [81][82] - Preclinical data supports the potential for ARV-102 to impact pathologic proteins associated with these diseases [41][42] - **KRAS G12D**: - The ARV-806 program aims to demonstrate superior efficacy compared to existing inhibitors, with a focus on overcoming compensatory upregulation seen in traditional therapies [119][120] Upcoming Milestones - **Data Releases**: Anticipated data from ongoing trials, including results from ARV-102 in Parkinson's disease patients and updates on ARV-806 [68][128] - **Phase 1b Trial**: Plans to initiate a phase 1b trial for progressive supranuclear palsy by mid-year [68] Conclusion - Arvinas is positioned as a leader in the development of PROTAC degraders, with a robust pipeline and strategic focus on differentiation and combination therapies. The company is actively pursuing partnerships and preparing for significant clinical data releases in the near future.

Summary of Arvinas Conference Call Company Overview - Arvinas is a leader in protein degradation technology, focusing on PROTAC degraders to target disease-causing proteins [3][2] - The company has been operational for over 10 years and is currently advancing multiple programs in clinical trials [3] Current Clinical Programs Phase 1 Programs - Arvinas has four active Phase 1 programs: 1. **LRRK2 Degrader** for neurodegeneration, particularly targeting Parkinson's disease [2] 2. **KRAS G12D Degrader** for solid tumors [2] 3. **BCL6 Degrader (ARV-393)** for hematological cancers [2] 4. A newly initiated **AR Degrader (ARV-027)** targeting polyglutamine repeat AR associated with Kennedy's disease [22][2] LRRK2 Program - The LRRK2 degrader is in two Phase 1 studies, with data readouts expected at the ADPD conference [9][12] - Initial data from healthy volunteers showed the ability to cross the blood-brain barrier and reduce LRRK2 levels in cerebrospinal fluid (CSF) [11][12] - The program aims to expand into progressive supranuclear palsy (PSP) based on genetic and biomarker evidence [19] ARV-393 (BCL6 Degrader) - The BCL6 program is in Phase 1 dose escalation, with initial responses observed in both B-cell and T-cell lymphomas [39] - The program aims to demonstrate superior efficacy through degradation rather than inhibition, as BCL6 is rapidly resynthesized [40] KRAS G12D Program (ARV-806) - The KRAS G12D program has completed enrollment in its Phase 1 trial, with initial data expected in 2026 [57][58] - Preclinical data suggests a 25-fold increase in effectiveness compared to traditional inhibitors, with a focus on reducing Myc and enhancing apoptotic markers [62][64] Partnerships and Commercialization - Arvinas is working with Pfizer to secure a commercialization partner for vepdegestrant, with expectations to finalize by early June [34][35] - The company is exploring alternative options if a partner is not secured before the PDUFA date [37] Strategic Focus - The company emphasizes differentiation in its clinical programs, aiming to bring unique and effective therapies to market rather than competing with existing options [80] - Future data updates will focus on LRRK2, KRAS, and ARV-393, with a commitment to responsible capital deployment [82][66] Market Position and Outlook - Arvinas is positioned strongly within the competitive landscape of oncology and neurodegeneration, with a robust pipeline and proven technology platform [83] - The company aims to leverage its unique PROTAC technology to address unmet medical needs and enhance patient outcomes [83]

Financial Data and Key Metrics Changes - The company reported $9.5 million in revenue for Q4 2025, a significant decrease from $59.2 million in Q4 2024, primarily due to a $40.3 million decline in revenue from the Novartis license agreement [19] - For the full year 2025, total revenue was $262.6 million, slightly down from $263.4 million in 2024 [19] - Cash equivalents and marketable securities at the end of Q4 2025 were just over $685 million, down from over $1 billion at the end of 2024 [18] Business Line Data and Key Metrics Changes - The company has four ongoing clinical trials across oncology and neurology, including the first-in-human trial of ARV-027, a polyQ-AR degrader [5] - ARV-102, a LRRK2 degrader, has shown over 50% reduction in LRRK2 in the CSF of healthy volunteers, indicating strong brain penetration [27] - ARV-806, targeting KRAS G12D, has demonstrated over 25-fold potency in reducing cancer cell proliferation compared to existing therapies [30] Market Data and Key Metrics Changes - The company is focusing on developing differentiated treatments in competitive areas, with a strong emphasis on clinical data to validate their approach [36] - The competitive landscape includes multiple programs targeting similar pathways, necessitating clear differentiation for success [36] Company Strategy and Development Direction - The company aims to maximize opportunities in core areas by focusing on differentiated treatments that provide significant patient benefits [10] - A strategic refocus on Phase I clinical programs has been implemented, with a commitment to only advance treatments that demonstrate clear differentiation [10] - The company plans to initiate a Phase 1B trial for ARV-102 in PSP and potentially a registrational trial by late 2026 [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong pipeline and financial position, anticipating multiple data readouts and clinical advancements in 2026 [4][23] - The company is committed to developing treatments that do not compromise on efficacy, safety, and tolerability, aiming for transformative impacts on patient care [10] Other Important Information - The company has suspended its stock repurchase program after buying back approximately 10 million shares for a total of $91.9 million [22] - Discussions with potential partners for the commercialization of vepdegestrant are ongoing, with expectations to finalize an agreement before the June 5th PDUFA date [9][72] Q&A Session Summary Question: What key data will determine if a program is differentiated? - Management indicated that differentiation will vary by program, with specific data points needed for each to establish superiority over competitors [34][36] Question: What should be expected from ARV-102 data at ADPD? - Management noted that the data will focus on safety and efficacy in Parkinson's patients, with expectations of demonstrating continued safety and biomarker engagement [49][50] Question: Will there be any dose modifications needed for ARV-393 in combination with glofitamab? - Management does not anticipate needing dose modifications but will proceed with caution and evaluate during the combination studies [63] Question: What are the early observations for ARV-393? - Early data show responses in patients with B and T cell lymphomas, with good degradation of BCL6, supporting continued development [85] Question: What is the strategy for the polyQ-AR degrader? - The company is exploring surrogate markers for SBMA and engaging with health authorities for potential future studies [89]

Financial Data and Key Metrics Changes - The company reported $9.5 million in revenue for Q4 2025, a significant decrease from $59.2 million in Q4 2024, primarily due to a $40.3 million decline in revenue from the Novartis license agreement [21] - For the full year 2025, total revenue was $262.6 million, slightly down from $263.4 million in 2024 [21] - Cash equivalents and marketable securities at the end of Q4 2025 were just over $685 million, down from over $1 billion at the end of 2024 [20] Business Line Data and Key Metrics Changes - The company has four ongoing clinical trials across oncology and neurology, including the first-in-human trial of ARV-027, a polyQ AR degrader [5] - ARV-102, a LRRK2 degrader, has shown over 50% reduction in LRRK2 in the CSF of healthy volunteers, indicating strong brain penetration [30] - ARV-806, targeting KRAS G12D, has demonstrated over 25-fold potency in reducing cancer cell proliferation compared to existing therapies [33] Market Data and Key Metrics Changes - The company is focusing on differentiated treatments in competitive areas, particularly in oncology and neurology, where there is significant unmet need [5][10] - The market for SBMA, targeted by ARV-027, is currently untapped with no approved treatments available [14] Company Strategy and Development Direction - The company has redefined its strategy to focus on developing treatments that are highly differentiated from existing options [4][10] - Plans include advancing ARV-102, ARV-806, ARV-393, and ARV-027, with a strong emphasis on achieving meaningful data readouts in 2026 [10][25] - The company aims to ensure that vepdegestrant is launch-ready if approved, while prioritizing its internal programs [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong financial position, allowing for continued investment in differentiated programs [19][25] - The upcoming year is expected to be pivotal, with multiple data readouts and clinical advancements anticipated [5][10] Other Important Information - The company has suspended its stock repurchase program after buying back approximately 10 million shares for a total of $91.9 million [24] - The company is working with Pfizer to select a third party for the commercialization of vepdegestrant, aiming for an agreement before the June PDUFA date [9][73] Q&A Session Summary Question: What key data will determine if a program is differentiated? - Management indicated that differentiation will be assessed on a program-by-program basis, with specific data points expected to emerge from ongoing trials [38][39] Question: What should be expected from ARV-102 data at ADPD? - The data will focus on safety and efficacy in Parkinson's patients, with expectations of demonstrating continued safety and biomarker engagement [51][52] Question: Will there be any dose modifications needed for ARV-393 in combination with glofitamab? - Management does not anticipate needing dose modifications, although they will proceed with caution during combination trials [63] Question: What are the early observations for ARV-393? - Early data show responses in patients with B and T cell lymphomas, indicating potential for further development [86]

Financial Data and Key Metrics Changes - The company reported $9.5 million in revenue for Q4 2025, a significant decrease from $59.2 million in Q4 2024, primarily due to a $40.3 million decline in revenue from the Novartis license agreement [19] - For the full year 2025, total revenue was $262.6 million, slightly down from $263.4 million in 2024 [19] - The company ended Q4 2025 with over $685 million in cash equivalents and marketable securities, down from over $1 billion at the end of 2024 [18] Business Line Data and Key Metrics Changes - General and administrative expenses decreased to $23 million in Q4 2025 from $34.1 million in Q4 2024, driven by reduced personnel and infrastructure costs [20] - Research and development expenses were $61.1 million in Q4 2025, down from $83.3 million in Q4 2024, reflecting cost-cutting measures [21] Market Data and Key Metrics Changes - The company is focusing on four ongoing clinical trials across oncology and neurology, with significant advancements expected in 2026 [4] - The company aims to develop differentiated treatments for underserved patient populations, particularly in the areas of Parkinson's disease and various cancers [4][12] Company Strategy and Development Direction - The company has redefined its strategy to focus on developing only highly differentiated treatments, emphasizing the importance of efficacy, safety, and tolerability [9] - The company plans to prioritize its clinical programs, specifically ARV-102, ARV-806, ARV-393, and ARV-027, while suspending its stock repurchase program to allocate resources more effectively [22][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong financial position, allowing it to maintain cash runway guidance into the second half of 2028 [24] - The company anticipates multiple data readouts and clinical advancements in 2026, which are expected to validate its strategy and enhance shareholder value [4][25] Other Important Information - The company has submitted its first New Drug Application, potentially leading to the first-ever FDA approval of a PROTAC degrader [3] - The company is working with Pfizer to select a third party for the commercialization and further development of vepdegestrant, aiming for a partnership before the June PDUFA date [8][72] Q&A Session Summary Question: What key data will determine if a program is differentiated? - Management indicated that differentiation will vary by program, with specific data points needed for each to establish superiority over competitors [36][39] Question: What should be expected from ARV-102 data at ADPD? - Management noted that the data will focus on safety and efficacy in Parkinson's disease patients, with expectations for continued safety and biomarker engagement [50][51] Question: Will there be any dose modifications needed for ARV-393 in combination with glofitamab? - Management does not anticipate needing dose modifications for ARV-393, although they will proceed with caution and monitor for any potential toxicity [63] Question: What are the early observations for ARV-393? - Management highlighted early evidence of efficacy in patients with B and T cell lymphomas, with a commitment to pursuing the product based on promising initial results [84]

Core Viewpoint - Arvinas, Inc. is set to review its fourth quarter and full year 2025 financial results and provide a corporate update on February 24, 2026, at 8:00 a.m. ET [1] Company Overview - Arvinas, Inc. is a clinical-stage biotechnology company focused on developing a new class of drugs based on targeted protein degradation [3] - The company utilizes its PROTAC (PROteolysis TArgeting Chimera) platform to create therapies that degrade disease-causing proteins by leveraging the body's natural protein disposal system [3] - Arvinas is advancing multiple investigational drugs through clinical development, including: - ARV-102, targeting LRRK2 for neurodegenerative disorders - ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers - ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma - Vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer [3]

Core Viewpoint - The appointment of Randy Teel, Ph.D., as President and CEO of Arvinas is expected to drive the company's strategy and innovation, positioning it for continued growth and momentum in the biotechnology sector [1][3]. Leadership Transition - Randy Teel succeeds John Houston, Ph.D., who is retiring but will remain on the Board and provide consulting services [2]. - Briggs Morrison, M.D., has been elected as the new Chair of the Arvinas Board of Directors [2]. Executive Background - Dr. Teel has been with Arvinas since 2018 and has over 20 years of experience in the biopharmaceutical industry, playing a key role in the company's IPO and strategic initiatives [3]. - His previous roles include Chief Business Officer and interim Chief Financial Officer, with experience at Alexion Pharmaceuticals and McKinsey & Company [3]. Strategic Focus - Dr. Teel aims to build on the existing momentum and focus on earlier stage clinical programs that have the potential to transform treatment paradigms for serious diseases [4]. - Under Dr. Houston's leadership, Arvinas achieved significant milestones, including the first positive pivotal results for a PROTAC degrader and raising over $2 billion through various funding avenues [4]. Pipeline and Future Goals - The company is advancing multiple investigational drugs, including ARV-102 for neurodegenerative disorders, ARV-393 for non-Hodgkin Lymphoma, and ARV-806 for mutated cancers [6]. - Anticipated critical milestones later this year include important clinical data from several drug candidates [5].

Core Insights - Pfizer anticipates a significant revenue decline due to the loss of exclusivity for key products between 2026 and 2030, including Eliquis, Vyndaqel, Ibrance, Xeljanz, and Xtandi, all facing patent expirations [1][9] - The company has bolstered its R&D pipeline through mergers and acquisitions, successful data readouts, and pivotal program initiations, positioning itself for sustainable growth post-LOE [1][7] Oncology Pipeline - Pfizer has advanced its oncology pipeline with several candidates in late-stage development, including vepdegestrant for ER+/HER2- metastatic breast cancer, atirmociclib for HR+/HER2- metastatic breast cancer, and sigvotatug vedotin for metastatic non-small cell lung cancer [2] - By 2030, Pfizer expects to have eight or more blockbuster oncology medicines in its portfolio [4] Non-Oncology Developments - In non-oncology areas, Pfizer is developing an mRNA flu/COVID combination vaccine and osivelotor for sickle cell disease, both in late-stage development [4] - The company is also expanding the labels of approved products like Padcev, which was recently approved by the FDA in combination with Merck's Keytruda for specific bladder cancer patients [5] Obesity Market Expansion - Pfizer is strengthening its presence in the obesity market, currently dominated by Eli Lilly and Novo Nordisk, through the $10 billion acquisition of Metsera and the in-licensing of YP05002, an oral GLP-1 receptor agonist [6] - The Metsera acquisition added four novel clinical-stage programs for obesity, expected to generate billions in peak sales [6] Competitive Landscape - Pfizer faces revenue headwinds from patent expirations but is positioned for long-term growth through its expanding late-stage pipeline in oncology and investments in obesity, vaccines, and rare diseases [7] - The oncology market is competitive, with major players like AstraZeneca, Merck, Johnson & Johnson, and Bristol-Myers also focusing on oncology sales [10][11][12][13] Financial Performance - Pfizer's stock has declined 7% over the past year, while the industry has seen a 16% increase [14] - The company's shares are trading at a forward price/earnings ratio of 8.18, below the industry average of 17.40 and its own 5-year mean of 10.39, indicating attractive valuation [16] - The Zacks Consensus Estimate for 2025 earnings has increased slightly to $3.10 per share, while the estimate for 2026 has decreased to $3.04 per share [18]

Summary of Arvinas Conference Call Company Overview - **Company**: Arvinas - **Industry**: Biotechnology, specifically focused on protein degradation therapies Key Points and Arguments Protein Degradation and Pipeline - Arvinas is recognized as the most advanced protein degrader company with a potential approval expected next year [1] - The company has partnered with Pfizer to jointly out-license the estrogen receptor degrader, vepdegestrant, which has a PDUFA date of June 5, 2026, for ESR1 mutant metastatic breast cancer [1] - Arvinas is advancing an early-stage PROTAC pipeline, including: - LRRK2 degrader (ARV-102) for Parkinson's disease and progressive supranuclear palsy (PSP) [1] - BCL6 degrader (ARV-393) targeting B-cell malignancies [1] - KRAS G12D degrader (ARV-806) [2] LRRK2 Degrader (ARV-102) - LRRK2 is a validated target for Parkinson's disease, with about 15% of familial cases linked to LRRK2 mutations [3] - The degradation of LRRK2 can address multiple pathological features associated with Parkinson's and PSP [5] - A phase 1 study demonstrated that doses of 20-80 mg/day achieved approximately 75% degradation of LRRK2 in healthy volunteers [9] - The company aims to start a phase 1b study in PSP in the U.S. next year, measuring biomarkers and clinical progression [15] BCL6 Degrader (ARV-393) - ARV-393 targets BCL6, a master regulator of B-cell maturation, which is involved in the development of malignancies like large B-cell lymphoma [22] - The company is in a phase 1 study and has seen complete responses (CRs) in patients [24] - Plans to combine ARV-393 with bispecific antibodies to enhance treatment efficacy [25] KRAS G12D Degrader (ARV-806) - Arvinas has demonstrated significant preclinical potency for ARV-806, with 25 to 40 times the potency compared to competitors [29] - The degrader approach may overcome resistance mechanisms seen with traditional inhibitors [30] New Developments - ARV-027 is a new polyQ AR degrader targeting spinal and bulbar muscular atrophy (SBMA), an orphan disease with a validated target [32] - The company plans to start a healthy volunteer study for ARV-027 next year [35] Financial Position - Arvinas ended the third quarter with a cash position of $788 million and has been repurchasing stock [37] - The company has sufficient cash to fund its programs into the second half of 2028 [37] Market Position and Future Outlook - The company is positioned to capitalize on the growing interest in protein degradation therapies and has a robust pipeline with multiple candidates in development [1][2][22] - The potential partnership for vepdegestrant could provide additional funding [38] Additional Important Information - The company is focused on addressing diseases with significant medical need, particularly in the context of PSP and Parkinson's disease, where there are currently no approved therapies [20] - The strategic focus on developing drugs that can be managed independently by a smaller biotech company is emphasized [34]